<div>GlaxoSmithKline Pharmaceuticals on Saturday (31 October) reported a 25.39 per cent dip in standalone net profit at Rs 96.05 crore for the quarter ended September 30.</div><div> </div><div>The company had posted a net profit of Rs 128.67 crore for the same period a year ago, GlaxoSmithKline Pharmaceuticals said in a filing to BSE.</div><div> </div><div>Standalone total income from operations also declined to Rs 700.09 crore for the quarter under review as against Rs 746.76 crore for the corresponding period of previous fiscal.</div><div> </div><div>Established in 1924 in India, GlaxoSmithKline Pharmaceuticals product portfolio includes prescription medicines and vaccines.</div><div> </div><div>The firm’s prescription medicines range across therapeutic areas such as dermatology, anti-infectives, gynaecology, diabetes, cardiovascular diseases, respiratory diseases and oncology.</div><div> </div><div>(PTI)</div>
